Lionel Hutz on Liquidia's patent battle $LQDA

Episode Summary

Executive Summary: The episode analyzes Liquidia (LQDA), a microcap biotech developing inhaled treprostinil for pulmonary hypertension, and the patent litigation that determines whether it can launch. The guests argue United Therapeutics’ key 793 patent is likely invalidated on appeal because Liquidia found prior disclosures in major libraries, meaning commercialization could begin in mid-2024 and create substantial upside if the drug proves differentiated.

Main Topics: Liquidia’s drug and market opportunity (Priority: 5/5): Liquidia is developing a dry powder inhaled treprostinil for rare pulmonary hypertension indications, targeting a severe disease with limited treatment options and meaningful unmet need. United Therapeutics’ incumbent position (Priority: 5/5): United’s Tyvaso is the dominant product, with a roughly $1B annual run-rate and strong economics, so any entrant threatens significant value. Patent and litigation structure (Priority: 5/5): The discussion explains the parallel district court case and PTAB IPR process, focusing on the 793 delivery patent and why induced infringement is the central issue. Why the 793 patent may be invalid (Priority: 5/5): Liquidia’s core argument is that the invention was publicly disclosed in conference abstracts and library records before the patent’s critical date, undermining patent validity under prior-art rules. Conflicting rulings and appeal path (Priority: 4/5): The district court upheld the patent while the PTAB invalidated it; the guests argue the PTAB view can still prevail on appeal and ultimately bind the district court. Commercialization timing and strategic delay (Priority: 4/5): Timeline uncertainty stems from rehearing, Federal Circuit appeal, and potential delay tactics, but the speakers think mid-2024 commercialization is plausible if Liquidia prevails. Upside, competition, and balance-sheet considerations (Priority: 4/5): The episode closes on market share potential, differentiated drug delivery, limits on generic flooding, and whether Liquidia has enough cash to reach launch.

Key Arguments: Liquidia’s market is attractive because pulmonary hypertension is rare, severe, and poorly served by current therapies, especially as patients move from oral drugs to inhaled treatment and then injections. The 793 patent is the critical barrier, but it may fail because the inventor’s own disclosures were published or cataloged before the patent filing date. The PTAB’s invalidation should not be dismissed just because the district court ruled differently; the appeal process can ultimately make the PTAB ruling controlling. Liquidia’s strongest validity argument is that multiple prestigious libraries cataloged the relevant abstracts, making them publicly accessible to skilled researchers. United’s counterarguments on conference disclosure and post-dated research aids are weaker than the library-record argument. The Federal Circuit usually affirms PTAB outcomes at high rates, which improves Liquidia’s odds if the PTAB reasoning is clarified. Liquidia may have a differentiated product due to its PRINT manufacturing technology, potentially supporting market share gains even without heavy price undercutting. The addressable patient population and turnover rate in the orphan disease market could support meaningful revenue despite the small total number of patients. United’s extra actions, including trade secret litigation, are likely delay tactics because each month of exclusivity is valuable. Liquidia’s current cash and potential non-dilutive funding may be enough to bridge to commercialization, though future financing is still likely.

Data Points: United Therapeutics Tyvaso run-rate: $1 billion annual run rate - Described as the incumbent product’s revenue scale as of Q3. Pulmonary arterial hypertension patient pool: ~12,000 patients - Estimated U.S. patient population for one target indication. Pulmonary hypertension with interstitial lung disease patient pool: ~30,000 patients - Estimated U.S. patient population for the second target indication. Alternative estimate on PH-ILD market size: Possibly double - Pulmonologists suggested the patient pool may be higher than the stated estimate. Federal Circuit PTAB affirmation rate: ~75% to 80% - Used to support the view that Liquidia has good odds on appeal. Potential commercialization timing: Mid-2024 - Management guidance/guest estimate if Liquidia wins the appeal process. Liquidia cash balance: ~$100 million - Approximate balance after an April equity raise. Patient/prescriber footprint: ~50 prescribers - Suggested by a shareholder as a rough match to Liquidia’s ~50-person sales force. Current patient persistence on Tyvaso: ~1.7 years - Average duration patients remain on the incumbent therapy, supporting market turnover. Potential market share: Upwards of 40% within 1–2 years - Bull case for Liquidia after launch, if product and access dynamics play out well. Potential value per 10% market share: ~$120 million revenue; ~4x multiple ≈ $4/share - Back-of-the-envelope valuation framework offered by the host. Patent expiration year: 2027 - Used to illustrate why every month of delay matters to United Therapeutics. Timeline for Federal Circuit decision after oral argument: ~40–42 days - Approximate turnaround cited for non-precedential cases. Critical date discussed for prior art: March 15 - Referenced in comparing library/research-aid publication timing. Research aid date mentioned: March 30 - Used to argue the aids were too late to prove pre-critical-date public availability.

Pivotal Quotes: "“the PTAB ruling is gonna hit the federal circuit... I expect that they are going to uphold the invalidation of the 793.”" — Lionel Hutz: On why the patent board’s invalidation is likely to survive appeal "“you published this, you made this known to the world. Too soon.”" — Lionel Hutz: Summarizing the core invalidity argument against the 793 patent "“I think Liquidia is in a great position to start gaining market share rapidly.”" — Lionel Hutz: On the commercial upside if the drug launches successfully

Implications: If Liquidia wins the patent appeal, it could launch into a large, underpenetrated orphan market with a differentiated inhaled product and meaningful upside. The case also highlights how patent validity, not just drug efficacy, can determine biotech value.